Dengvaxia

The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization programme after the French drugmaker said it could actually worsen the disease in some cases.

The study found that the dengue vaccine with the trade name Dengvaxia can reduce illness and hospitalisation by 20 to 30 per cent in places where there is high transmission of dengue. The initial exposure to the virus from the vaccine primes the immune system, so when they are infected again, the symptoms are more likely to be severe.

Brazil became the first South American country Monday to authorize the world's first-ever dengue fever vaccine, which its French manufacturer says has the potential to save hundreds of lives here.

Sanofi Pasteur, the vaccines division of Sanofi, on Wednesday said the Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for the prevention of dengue in Asia.

Dengue fever, the world's fastest growing mosquito-borne disease, has spread its wings from being a tropical disease, endemic in just nine countries, to a worldwide threat.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

The first-ever vaccine against dengue fever has been cleared for use in Mexico, French manufacturer Sanofi said today.

The World Health Organization said on Monday it hopes to review safety data on Sanofi's dengue vaccine this month, while the Philippines ordered an investigation of its now suspended massive immunization programme after the French drugmaker said it could actually worsen the disease in some cases.

The study found that the dengue vaccine with the trade name Dengvaxia can reduce illness and hospitalisation by 20 to 30 per cent in places where there is high transmission of dengue. The initial exposure to the virus from the vaccine primes the immune system, so when they are infected again, the symptoms are more likely to be severe.

Brazil became the first South American country Monday to authorize the world's first-ever dengue fever vaccine, which its French manufacturer says has the potential to save hundreds of lives here.

Sanofi Pasteur, the vaccines division of Sanofi, on Wednesday said the Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for the prevention of dengue in Asia.

Dengue fever, the world's fastest growing mosquito-borne disease, has spread its wings from being a tropical disease, endemic in just nine countries, to a worldwide threat.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.

The first-ever vaccine against dengue fever has been cleared for use in Mexico, French manufacturer Sanofi said today.